AI on Living Skin: Outer Biosciences’ Game‑Changing Biotech Play

Outer Biosciences has entered investors’ radar as one of the few biotech ventures offering AI‑driven formulation discovery by keeping human skin alive in the lab for months.

Scientific Breakthrough of the Live‑Tissue Platform

The company sources human skin discarded after elective surgery through IRB‑approved biobanks and extends tissue viability to 30 days with a proprietary nutrient‑waste management system—far beyond the industry norm of a few days.

■30‑day viable tissue enables observation of week‑long processes such as collagen remodeling and pigment changes.

■The tissue retains its day‑zero architecture, preserving epidermal, stromal and immune molecular programs.

■Sources are obtained on a cost‑recovery basis from NIH‑funded networks; no outright purchase occurs.

AI Loop: Predict, Test, Feed‑Back

The closed‑loop model predicts untested chemicals, runs them on the living skin, and feeds the outcomes back into the AI for continuous learning.

■In the “brute‑force” phase, a handful of candidates emerged over 18 months.

■After AI integration, a new candidate is generated roughly every six weeks.

■Currently 6 active leads and dozens of “hits” sit in the pipeline.

Founder & Strategic Alliances: Michael Polansky and Lady Gaga

Polansky, a Harvard‑trained former Bridgewater and Founders Fund executive, also serves as the creative and romantic partner of pop icon Lady Gaga. Their dual relationship fuels cross‑company collaborations between Outer Biosciences and Haus Labs.

■Polansky founded Outer Biosciences in 2022 with co‑founders Kyung‑Jin Jang (Chief Scientist) and Chris Hinojosa (CTO).

■Haus Labs, with 70 employees, is thriving in the cosmetics space; it leverages Outer’s data to co‑develop novel active ingredients.

■The firm also draws support from large‑scale initiatives like the Parker Institute for Cancer Immunotherapy.

Market & Financial Outlook: Cosmeceuticals and Investment Appeal

The live‑skin platform creates a new value chain not only for cosmetics but also for drug discovery and dermatology. Investors view the rapid candidate turnover and ethical data sourcing as strategic differentiators.

■With only 200‑plus approved active ingredients across OTC categories, the market presents a sizable innovation gap.

■Outer’s model promises one new formulation candidate per month, boosting potential licensing revenue and partnership opportunities.

■The company targets a Series A raise of $10‑15 M within the next 12 months.

Markets are beginning to see the combination of AI with ex‑vivo human tissue as a fresh framework for long‑term biotech investments. While data quality and supply‑chain ethics remain risk factors, the speed of prototyping and licensing upside position Outer Biosciences firmly in the “high‑growth” segment for venture capitalists. – Deniz Arslan, Venture Capital Partner